Canakinumab, ACZ885 + Triamcinolone acetonide
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Gouty Arthritis
Conditions
Gouty Arthritis
Trial Timeline
Jun 20, 2011 → May 19, 2015
NCT ID
NCT01362608About Canakinumab, ACZ885 + Triamcinolone acetonide
Canakinumab, ACZ885 + Triamcinolone acetonide is a phase 3 stage product being developed by Novartis for Gouty Arthritis. The current trial status is terminated. This product is registered under clinical trial identifier NCT01362608. Target conditions include Gouty Arthritis.
What happened to similar drugs?
1 of 6 similar drugs in Gouty Arthritis were approved
Approved (1) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01362608 | Phase 3 | Terminated |
Competing Products
9 competing products in Gouty Arthritis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Canakinumab pre-filled syringe + Canakinumab lyophilized powder + Triamcinolone Acetonide + Placebo | Novartis | Phase 3 | 40 |
| Lumiracoxib | Novartis | Approved | 43 |
| canakinumab + dexamethasone | Novartis | Phase 2 | 35 |
| ACZ885 + Triamcinolone acetonide 40 mg | Novartis | Phase 3 | 40 |
| Canakinumab 150mg in prefilled syringe | Novartis | Phase 3 | 40 |
| Canakinumab | Novartis | Phase 2 | 35 |
| ACZ885 + Triamcinelone acetonide | Novartis | Phase 3 | 32 |
| Indomethacin + Celecoxib + Celecoxib + Celecoxib | Pfizer | Phase 3 | 40 |
| Anakinra 100 mg + Triamcinolone Acetonide 40 mg + Placebo to Anakinra 100 mg + Placebo to Triamcinolone Acetonide 40 mg | Swedish Orphan Biovitrum | Phase 2 | 35 |